September 2004
"ISPOR e-BULLETIN" provides updates of recent ISPOR activities and events. For detailed information on ISPOR activities, members are encouraged to go to www.ispor.org.

Please pass these updates along to your colleagues.

  eBulletin Index

 

 NEW THIS MONTH

**NEW**    ISPOR 7th Annual European Congress Final Program available online

**NEW**    ISPOR 7th Annual European Congress Personal Program Scheduler now available

**NEW**    ISPOR 10th Annual International Meeting Call For Abstracts and Preliminary Program

**NEW**    ISPOR Asia Consortium Founded & Executive Committee Chairs elected

**NEW**    ISPOR CONNECTIONS Vol. 10, Issue 4 July/August 2004 now online

**NEW**    ISPOR Special Interest Group Activities

**NEW**    7 New Positions at ISPOR Employment Website

**NEW**    Senior Consultant and Consultant with Applied Health Outcomes Positions Available

**NEW**    ISPOR Advisory Councils’ Missions and Activities at ISPOR website

**COMING SOON**    Value in Health Vol. 7 No. 5 (September/October) featured articles

 

 

ISPOR ONGOING ACTIVITIES

 

1.       Publications

2.       Meetings and Congresses

3.       Educational Activities

4.       Student News

5.       ISPOR Special Interest Groups

6.       Committee and Task Force Activities

7.       Hot Topics

8.       Important Dates to Remember

9.       Employment in Pharmacoeconomics and Outcomes Research

10.    Membership

 


  1. PUBLICATIONS

Top

 

 

VALUE IN HEALTH

 

Value in Health: Volume 7, Issue 5, September/October 2004 will be available later this month online and available this month at: http://www.ispor.org/valueinhealth_index.asp. 

 

Featured in this Issue…

 

VALUES USED IN COST-EFFECTIVENESS COMPARISON ARE NOT "WEIGHTED" EQUAL. PROCEED WITH CAUTION 

HT Hatoum, JE Brazier, KS Akhras  

Economic evaluation of health programs consists of comparing alternative interventions in terms of costs and consequences(outcomes) in order to better inform decision makers. One such a program, cost-utility analysis, incorporates the measured preferences (utilities) of individuals for health outcomes of the alternative interventions, using quality-adjusted life years (QALYs). QALYs incorporate changes in quantity of life, as measured in years, with changes in quality of life, as measured in utilities. Utilities may be obtained from a variety of sources including the health utilities index (HUI), or from transforming the SF-36 to a utility measure, the SF-6D.  

A recent study, “Comparison of the HUI3 with the SF-36 Preference Based SF-6D in a Clinical Trial Setting” published in Value in Health (Volume 7, Issue 5), by Hatoum and colleagues, reported on utilities measured in a double-blind, multi-national phase III clinical trial in patients undergoing percutaneous coronary intervention prior to hospital discharge and 6 months thereafter.  In these patients, the HUI3 and the SF-6D generated different estimates of utilities, albeit both were found able to measure changes in patients’ conditions over time. In this study, the gain in utilities from treatment was lower when using the SF-6D. Since utilities form the basis for calculating QALYs, measures deployed are not interchangeable for use in cost-utility analysis.

 

CLINICAL OUTCOMES AND COSTS OF TREATMENT WITH RISPERIDONE VERSUS OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA

 

M. Vera-Llonch M, T. Delea, E. Richardson, M. Rupnow, A. Grogg, G. Oster

 

Side effects are an important cause of noncompliance and therapy switching in patients receiving antipsychotic medications; as a result, they can increase costs of care and decrease the effectiveness of pharmacotherapy.  In this study, two widely-used atypical antipsychotics‑‑risperidone and olanzapine‑‑were compared in terms of their side effects and associated impacts on outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders.  The authors developed an analytic model that focused attention on the likelihood of therapy switching and discontinuation over one year as a result of treatment-emergent side effects, including extrapyramidal symptoms, symptomatic prolactin-related disorders, type II diabetes mellitus, and weight gain.  The model was estimated using information from randomized controlled trials and published recommendations.  Findings suggest that while patients who receive risperidone are more likely to experience extrapyramidal symptoms and symptomatic prolactin-related disorders, those treated with olanzapine are more likely to experience greater gains in body weight, and a slightly higher risk of diabetes mellitus.  Rates of therapy discontinuation and costs of care per month of therapy also were higher among olanzapine patients. These findings may be of interest to clinicians and others interested in outcomes and costs of mental health treatment.

 

 

CURRENT DECISION-ANALYTIC MODELS FOR THE EVALUATION OF INTERVENTIONS IN PARKINSON'S DISEASE PROVIDE VALUABLE INSIGHTS BUT DO NOT COVER THE LARGE SPECTRUM OF CLINICALLY RELEVANT OUTCOMES

 

Uwe Siebert, Bernhard Bornschein, Tobias Walbert, Richard C. Dodel

 

When long-term outcomes of medical interventions are uncertain and a treatment decision must be made, decision-analytic models are often used to aid decision making. In a recent study, “Systematic Assessment of Decision Models in Parkinson's Disease” funded by the German Federal Ministry of Education and Research and published in Value in Health, Volume 7, Issue 5, an interdisciplinary expert group investigated the design of decision models in Parkinson's disease. Uwe Siebert from the MGH Institute for Technology Assessment at Harvard Medical School in Boston and his colleagues from the University of Bonn and the Public Health Research and Coordinating Center in Munich reviewed the literature and identified eight models evaluating different antiparkinsonian treatments. “We found that several different methodological approaches have been used to model the effects of treatment for Parkinson’s disease; each of these studies has its distinct value and we can learn from them,” says Siebert. “Interestingly, all models included economic outcomes, but some ignored effects on health-related quality of life.” Richard Dodel, senior neurologist at the University of Bonn and Head of the Health Economic Working Group of the Competence Network Parkinson-Syndromes, stresses “currently available models do not explicitly capture the large spectrum of clinically relevant symptoms that physicians must consider in daily clinical decision making.” In their paper, the investigators recommend increasing model validation efforts and they provide suggestions for future modeling in Parkinson’s disease.

 

 

 ISPOR CONNECTIONS

 

ISPOR CONNECTIONS: Volume 10, Issue 4, July/August 2004 is now available online to the public at: http://www.ispor.org/news/index_new.asp.  Included in this issue:

 

Incoming Presidential Address:  Liven Annemans, MSc, PhD, HEDM-IMA, Brussels, Belgium, 2004-2005 ISPOR President

 

Pharmacoeconomic Guidelines Around the World: Tony Yen-Huei Tarn, MS, PhD, Visiting Scholar and Associate Professor, School of Pharmacy, National Defense Medical Center, Taiwan, Republic of China, and Marilyn Dix Smith, RPh, PhD, ISPOR Executive Director, Lawrenceville, NJ, USA

 

Publication of Pharmacoeconomic Data Submitted to Reimbursement or Clinical Guidelines Agencies: Josephine Mauskopf, PhD, RTI Health Solutions, RTP, NC, USA, and Michael Drummond, PhD, Centre of Health Economics, University of York, York, UK

 

 

HEALTH CARE COST, QUALITY, AND OUTCOMES: ISPOR BOOK OF TERMS

 

 

This ISPOR publication includes more than 100 detailed monographs covering over 400 terms used in health care delivery, management, and regulation, as well as health care outcomes research including clinical, economic, and quality-of-life research terms. ISPOR member discounted price is $36.00; a 40% discount!  Student/Library/Academic discounted price: $33.00 (a 45% discount). On-line ordering is now available at: http://www.ispor.org/publications/lexicon_index.asp.  Contact Stephen Priori at spriori@ispor.org for information on orders over 1000. 

 


 

 

  1. ISPOR MEETINGS AND CONGRESSES

Top

   

**NEW**7TH ANNUAL EUROPEAN CONGRESS FINAL PROGRAM AVAILABLE ONLINE

24-26 October 2004, CCH Congress Centrum Hamburg, Hamburg, Germany

Early Registration Deadline: 28 September 2004

 

PROGRAM HOT TOPICS

·         DISEASE MANAGEMENT PROGRAMS: THE CONCEPT AND EXPECTATIONS BY THE MINISTRY
Speaker
: Dr. Klaus Theo Schroeder, State Secretary, Federal Ministry for Health and Social Security, Bonn, Germany (1st Plenary Session, Sunday 24 October 13:15-15:00)

·         ALTERNATIVES TO THE FOURTH HURDLE: CLINICAL AND COST-EFFECTIVENESS ANALYSES IN EUROPE: BRIDGING THE GAP BETWEEN SCIENCE, INDUSTRY AND POLICY MAKERS
Speaker: Kees de Joncheere, Regional Adviser, Health Technology and Pharmaceuticals, WHO Regional Office, Copenhagen, Denmark (2nd Plenary Session, Monday 25 October 9:00-10:30)

·         REGULATORY PERSPECTIVES ON TRANSLATING PRO MEASURES
Speaker: Laurie B. Burke RPh, Director, Study Endpoints and Label Division, US Food and Drug Administration, Rockville, MD, USA (Quality of Life Forum, Monday 25 October 8:00-9:00)

·         INDUSTRY'S VS. STATUTORY HEALTH INSURANCE'S VS. UNIVERSITY'S RESEARCH INTERESTS – IS THERE MUTUAL BENEFIT IN EPIDEMIOLOGICAL AND OUTCOMES RESEARCH?
Speakers: Bernd Brüggenjürgen MD,Mph, Alpha Care Gmbh, Celle, Germany; Wolfgang Meyer-Sabellek Prof, PhD Astrazeneca, Wedel, Germany; Christoph Straub MD, Techniker Krankenkasse, Hamburg, Germany; Stefan N. Willich Prof, PhD, University Medicine Berlin, Charité, Berlin, Germany (Issue Panel, Monday 25 October, 15:45-16:45)

·         DO DECISION-MAKERS HAVE LESS CREDIBILITY WITH MODELING RESULTS?
Speakers: Uwe Siebert MD, Mph, Msc, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA and Institute For Medical Informatics, Biostatistics, and Epidemiology, University Of Munich, Munich, Germany (Issue Panel, Monday 25 October, 17:00-18:00)

 

PROGRAM KEY FEATURES:

·         Contributed Poster presentations Session I:

http://www.ispor.org/congresses/germany1004/posters1.asp

·         Contributed Poster presentations Session II:

http://www.ispor.org/congresses/germany1004/posters2.asp

·         64 Contributed Podium Presentations

·         Contributed Issues Panels

·         Contributed Workshops          

·         Medical Device & Diagnostics - Central & Eastern European Forums

 

Complete Congress Final Program available online at: http://www.ispor.org/congresses/germany1004/index.asp.

 Sign up for Exhibit Space, contract available online at

Sponsorship Opportunities still available, for more information go to:

 

 

**NEW** ISPOR 7th ANNUAL EUROPEAN CONGRESS PERSONAL PROGRAM SCHEDULER NOW AVAILABLE

 

To benefit Congress attendees ISPOR has a new feature for the ISPOR 7th Annual European Congress in Hamburg, Germany, the Personal Scheduler.  Now you are in control of what events and sessions you would like to attend with this unique planning tool.

 

With just the click of your mouse, the ISPOR Personal Scheduler will allow you to maximize your time at the congress by:

• searching or browsing events scheduled for this meeting

• creating your own individual schedule of events

• checking for conflicts

recording notes

• downloading to your Personal Digital Assistant (PDA).

 

The ISPOR Personal Program Scheduler is available at:

 

The Personal Program Scheduler is a free service provided to those registered to attend the ISPOR 7th Annual European Congress from 24-26 October in Hamburg, Germany at the CCH Congress Centrum Hamburg.

 

10TH ANNUAL INTERNATIONAL MEETING

May 15-18, 2005, Marriott Wardman Park Hotel, Washington, DC, USA

 

NEW** ISPOR 10TH ANNUAL INTERNATIONAL MEETING CALL FOR ABSTRACTS

http://www.ispor.org/meetings/washington0505/index.asp

Abstract Submission begins: October 1, 2004 – Abstract Submission Deadline: January 10, 2005.


 

  1. EDUCATION ACTIVITIES

Top

            ISPOR 7th Annual European Congress Short Courses

 

Saturday 23 October Short Courses, 23 October:

·         The Analysis and Interpretation of Quality of Life and Patient Reported Outcomes 

·         Pharmacoeconomics for the Health Care Decision-Makers

·         Elements of Pharmaceutical Pricing

·         Utility Measurements (Preference-based Techniques)

·         Cost Estimation and Assessing Financial (Budget) Impact of New HealthCare Technologies

 

For Short Courses descriptions, go to: http://www.ispor.org/congresses/germany1004/sc231004.asp

           

 

Sunday Short Courses, 24 October:

·          European Databases and Retrospective Database Analysis

·         International Studies in Patient-Reported Outcomes

·         Health Care and Reimbursement Systems in Europe

·         Pharmacoeconomic Modeling

·         Bayesian Methods in Economic Evaluations

 

For Short Course descriptions, go to: http://www.ispor.org/congresses/germany1004/sc241004.asp

 

           

ISPOR Distance Learning Program on the ISPOR website:

            ISPOR Distance Learning Program

 

The following modules are available:

 

 Pharmacoeconomics

  • The Role of Pharmacoeconomics (FREE)

 

Pharmacoeconomic Evaluations &  Methods

  • Cost Analysis in Pharmacoeconomics (I) – The Classification of Costs
  • Cost Analysis in Pharmacoeconomics (II) – The Health Care Production Function
  • An Introduction to Decision Theory
  • Markov Modeling in Decision Analysis
  • Evaluating a Pharmacoeconomic Study
  • Discounting Costs and Benefits
  • Modeling in Pharmacoeconomics

 

Cost-Effectiveness Analysis

  • Cost-Effectiveness Modeling in Pharmacoeconomics  
  • Interpreting Cost-Effectiveness Claims

 

Cost-Benefit Analysis

  • Theoretical Foundations of Cost Benefit Analysis
  • Measuring Willingness-to-Pay

 

Cost-Utility Analysis

  • Theoretical Foundations of Cost-Utility Analysis
  • Measuring Values and Utilities
  • Quality Adjusted Life Years (QALYs)

 

Humanistic Outcomes (Utilities, Health-related Quality of Life, Patient-reported Outcomes, Patient Preferences)

  • A Typology of Outcomes Instruments
  • The SF-36 Instrument
  • The Health Utilities Index

 

Study Design in Pharmacoeconomics

  • Study Design in Pharmacoeconomic Analysis
  • Experimental Designs
  • Non-Experimental Designs

 

Guidelines and Reference Standards

  • Guidelines and Reference Standards in Pharmacoeconomics
  • The Australian Guidelines for Formulary Submissions
  • Managed Care Formulary Submission Guidelines in the United States 
  • Responding to Managed Care Guidelines in the United States
  • Guidelines Case Study: Blue Cross and Blue Shield of Colorado and Nevada

 


 

  1. STUDENT NEWS

Top

  

For more details on the ISPOR Student Network, please visit: http://www.ispor.org/student/student_index.asp

        

 


 

 

  1. ISPOR SPECIAL INTEREST GROUPS (SIG)

Top

 

MANAGED CARE_PBM SIG

 

For more details, please visit http://www.ispor.org/sigs/sigsindex.asp

 

CLINICAL PRACTICE SIG

 

For more details, please visit: http://www.ispor.org/sigs/sigsindex.asp

 

HEALTH TECHNOLOGY ASSESSMENT SIG

 

**NEW** Chair – Frank Papatheofanis, MD, MPH, PhD

Director of the Advanced Medical Technology Assessment & Policy Program and
Associate Professor of Radiology and Economics, University of California at San Diego.

 

For more details on the SIG, please visit http://www.ispor.org/sigs/hta.asp

 

RISK MANAGEMENT SIG

 

The SIG is developing a survey on acceptable risk, specifically how risk standards are set; for example: societal assessment, patient decision-making, cost benefit analysis, or professional judgment.   Look for it soon.

 

For more details, please visit: http://www.ispor.org/sigs/rm.asp

 

MEDICATION COMPLIANCE SIG

**NEW** Forum
This SIG is organizing a Compliance forum on Issues in Medication Compliance and Persistence Research at the 7th European Congress.

            For more details, please visit: http://www.ispor.org/sigs/medication.asp

 

QUALITY OF LIFE SIG

**NEW** QOL Research Initiatives Webpage
Review the papers, symposiums, taskforce reports and other QOL SIG
accomplishments in the areas of Patient-Reported Outcomes and Population Health.
http://www.ispor.org/research_initiatives/qol_initiatives.asp

**NEW** Forum
This SIG is organizing a QOL forum: Emerging Issues in PRO Research at the 7th European Congress.  

            For more details, please visit: http://www.ispor.org/sigs/qol.asp


PATIENT REGISTRY SIG

 

              For more details, please visit: http://www.ispor.org/sigs/patient_registr.asp

 

Special Interest Group membership is open to ALL ISPOR members.

To JOIN any SIG: http://www.ispor.org/sigs/joinsig.htm

 


 

 

  1. ISPOR COMMITTEE AND TASK FORCE ACTIVITIES

Top

 

**NEW** ISPOR ADVISORY COUNCILS’ MISSIONS, MEMBERS, AND ACTIVITIES NOW AT THE ISPOR WEBSITE

 

Information on the Health Science Policy Council, the Institutional Council, the Health Care Strategy Council, the European Medical Device & Diagnostics, and the U.S. Medical Device & Diagnostics Council can now be accessed on the ISPOR website under the pull down tab labeled “Advisory Councils”. 

 

**NEW** ISPOR ASIA CONSORTIUM FOUNDED & EXECUTIVE COMMITTEE CHAIRS ELECTED

 

The ISPOR Asia Consortium consists of individuals interested in the science of pharmacoeconomics and outcomes research and its use in health care decisions in Asia.  Its mission, being consistent with the mission of the Society, is to advance the science of pharmacoeconomics and health outcomes research in the Asia region, to translate pharmacoeconomics and outcomes research results into practice, and to encourage countries in the region to allocate scarce healthcare resources wisely, fairly, and efficiently.

The 2004-2006 ISPOR Asia Consortium Executive Committee Chair is Gordon Liu, PhD, Professor and Chair, Depot of Health Economics and Management, Peking University Guanghua School of Management, Beijing P.R China and University of North Carolina at Chapel Hill.

The 2004-2006 ISPOR Asia Consortium Executive Committee Chair-elect and 2006-2008 Chair is Kenneth KC Lee,  JP, BSc(Pharm), MPhil, PhD, Professor, School of Pharmacy,

Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T.,Hong Kong, China.

 

For founding members, activities and more, visit: http://www.ispor.org/consortiums/asia.asp

 

If you are interested in joining the ISPOR Asia Consortium, email your request to asiaconsortium@ispor.org.

 


  1. HOT TOPICS

Top

 

MEDICARE LOOKS FOR WAYS TO BOOST QUALITY CARE COMMENTS SOUGHT ON NEW PLAN FOR QUALITY IMPROVEMENT ORGANIZATONS

 

September 2, 2004 –The Centers for Medicare & Medicaid Services today took another important step to assure that every patient receives the right care at the right time with a new proposal for its Quality Improvement Organizations (QIOs).

For full text of the article, go to: http://www.cms.hhs.gov/media/press/release.asp?Counter=1186

 

 


 

 

  1. IMPORTANT DATES TO REMEMBER

Top

 

 

September 28, 2004Early registration deadline for the 7th Annual European Congress. To register, go to: http://www.ispor.org/members/events/closed.asp

 

October 1, 2004 - Abstract Submission begins for the ISPOR 10th Annual International Meeting.

 

October 24-26, 2004 – ISPOR 7th Annual European Congress, CCH Congress Centrum Hamburg, Hamburg, Germany.

 

 


  1. EMPLOYMENT

Top

**NEW**7 NEW POSITIONS AT THE ISPOR WEBSITE Careers

 

            Advertise your positions on ISPOR Website (up to 1 million hits per month)

 

Participate in the PRAP (Professional Recruitment Center) at the 7th Annual European Congress! For more info, go to: Careers

 

**NEW** Senior Consultant and Consultant with Applied Health Outcomes Positions Available:

 

Senior Consultant

 

Applied Health Outcomes is currently recruiting for a Senior Consultant, for our Palm Harbor, Florida office.  Applied Health Outcomes is the premier provider of strategies and services that measure and communicate the value of pharmaceuticals and other healthcare technologies through expertise, commitment and integrity.

 

This position requires an individual with 3-5 years experience as a consultant in health economics and outcomes research or equivalent pharmaceutical industry experience.  A clinical background is preferred. Responsibilities include project management, economic modeling, research design, and development of research proposals, study reports, and manuscripts.  Ideal candidates will possess an advanced healthcare degree, research training (PhD, Masters, Fellowship) and have tangible experience with aforementioned job responsibilities.

 

Consultant

 

Applied Health Outcomes is currently recruiting for a Consultant, for our Palm Harbor, Florida office.  Applied Health Outcomes is the premier provider of strategies and services that measure and communicate the value of pharmaceuticals and other healthcare technologies through expertise, commitment and integrity.

 

This position requires an individual with expertise in health economics and outcomes research. A clinical background is preferred.  Responsibilities include content development and project implementation for a variety of services to include economic models, database studies, formulary dossiers, etc.  Ideal candidates will possess an advanced healthcare degree, research training (PhD, Masters, Fellowship) and have tangible experience with the aforementioned job responsibilities.

 

EOE with excellent compensation package including competitive salary and comprehensive benefits package.

 

Qualified candidates should submit letter of interest, curriculum vitae and salary requirements to:  Timothy S. Regan, RPh, CPh, Associate Director, Applied Health Outcomes, 3488 East Lake Road, Suite 201, Palm Harbor, FL 34685 USA, Tel: 727-771-4129, Fax: 727-771-4145, Email: tregan@applied-outcomes.com.


  1. ISPOR MEMBERSHIP

Top

Update your email address at https://www.ispor.org/members/MemberProfile.aspx! Your email address is required as part of your log in information in the members only section of the ISPOR website.

 


eBulletin Index